Additionally, Cancer Genetics noted that last week it sold off its clinical laboratory business to siParadigm, a specialty reference laboratory, for about $1 million.
Interpace Diagnostics' ThyGeNext and ThyraMir thyroid cancer assays are now covered for about 2.5 million patients in Philadelphia and Southeastern Pennsylvania.
The firm said its growth was driven in part by increasing sales volumes of its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.
With the approval of its ThyraMIR diagnostic assay, the firm said that physicians will have access to its thyroid product suite across several specimen types.
The firm will use the proceeds for working capital, capital payments, business development, research and development payments, and technology and business acquisitions.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
